Evaluating Anti-Xa Targets and Outcomes in Arterial Interventions – JTH
Journal of Thrombosis and Haemostasis (JTH) shared on LinkedIn about a recent article by Max Hoebink, et al, adding:
”Clinical Applicability of Anti-Xa Measurements to Monitor Unfractionated Heparin Activity During Arterial Procedures: A Scoping Review
This scoping review of 55 reports finds that while anti-Xa is a reliable reference test for heparin monitoring during arterial procedures, optimal target levels and their correlation with clinical outcomes remain poorly defined.”
Title: Clinical applicability of anti-Xa measurements to monitor unfractionated heparin activity during arterial procedures: a scoping review
Authors: Max Hoebink, Tom Steunenberg, Sjoerd Smit, Henrike Hamer, Arno Wiersema, Kak Khee Yeung, Vincent Jongkind
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 4, 2026, 18:49Børge Nordestgaard: Lp(a) Remains a Risk Factor Across the Lifespan
-
Sep 4, 2026, 18:22Tareq Abadl: The Clinical Meaning of C3 and C4
-
Sep 4, 2026, 18:16How Mutant p53 Hijacks VWF Expression in Tumor Cells – JTH
-
Sep 4, 2026, 18:08Simon Kraler: Can the Adrenomedullin System Predict Cardiogenic Shock Before It Happens?
-
Sep 4, 2026, 17:56Maxime Dely: Why Every Blood Donation Matters
-
Sep 4, 2026, 17:28Shinya Goto: When Cardiovascular Risk Gets Lower, RCTs Get Harder
-
Sep 4, 2026, 16:55New Orleans Is Calling ASH26 Is Near
-
Sep 4, 2026, 16:48ESC Congress 2026 – My Top 20 Lipidology Highlights Shaping the Future of Cardiovascular Prevention – Pablo Corral
-
Sep 4, 2026, 16:38Felice Gragnano։ Turning Cardiovascular Risk Into Action